|
ISEV Board Financial Disclosures
Elected members of the ISEV Board of Directors are required to report any relevant financial relationships with industry. This is done on an annual basis, and leaders are asked to report any new relationships as soon as they arise.
The following leaders reported the following relevant financial relationships. These disclosures were reviewed and no relationships were found to present a conflict of interest:
- Edit Buzas, Sphere Gene Therapeutics Inc, (Advisory Board), Scientific Advisory Board of ReNeuron, UK (Member)
- Jan Lotvall, Exocure Biosciences (Equity), ExoCoBio (Consulting Compensation), Clara Biotech (Consulting Compensation) and Nanoview (Consulting Compensation)
- Kenneth Witwer, Ad hoc consulting for networks including Guidepoint, Kinetcos (Consulting Compensation), Ad hoc private consulting as Kenneth W. Witwer (Consulting Compensation), Journal of Extracellular Vesicles (Associate Editor), Interdisciplinary Medicine Wiley (Associate Editor), Journal of Alzheimer's Disease (Associate Editor), AIDS (Board Member), Clincal Chemistry (Board Member), ShiftBio (Advisory Board), Exopharm Limited (Advisory Panel) and Greenlight Biosciences (Consulting Compensation),
- Sai Kiang Lim, Paracine Therapeutics, (Founding Equity)
- Takahiro Ochiya, Theoria Science Inc., (Salary)
- Susmita Sahoo, Evox, UK (Sponsored Research)
The following leaders had no financial relationships to report:
- Ana Claudia Torrecilhas
- Andreas Möller
- Andy Hill
- Benedetta Bussolati
- Clotilde Thery
- Deborah Goberdhan
- Houjian Cai
- Joshua Welsh
- Juan Falcon-Perez
- Metka Lenassi
- My Mahoney
- Qing-Ling Fu
- Rienk Nieuwland
- Sujata Mohanty
- Tom Driedonks
Last updated summer 2023.
|
